MA53272A - Procédé de préparation d'une formulation pharmaceutique d'anticorps - Google Patents

Procédé de préparation d'une formulation pharmaceutique d'anticorps

Info

Publication number
MA53272A
MA53272A MA053272A MA53272A MA53272A MA 53272 A MA53272 A MA 53272A MA 053272 A MA053272 A MA 053272A MA 53272 A MA53272 A MA 53272A MA 53272 A MA53272 A MA 53272A
Authority
MA
Morocco
Prior art keywords
preparing
antibody formulation
pharmaceutical antibody
pharmaceutical
formulation
Prior art date
Application number
MA053272A
Other languages
English (en)
Inventor
Bryan Dransart
Ashutosh Sharma
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA53272A publication Critical patent/MA53272A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA053272A 2018-08-10 2019-08-09 Procédé de préparation d'une formulation pharmaceutique d'anticorps MA53272A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862717357P 2018-08-10 2018-08-10

Publications (1)

Publication Number Publication Date
MA53272A true MA53272A (fr) 2021-11-17

Family

ID=67734839

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053272A MA53272A (fr) 2018-08-10 2019-08-09 Procédé de préparation d'une formulation pharmaceutique d'anticorps

Country Status (14)

Country Link
US (2) US20210308265A1 (fr)
EP (1) EP3833327A1 (fr)
JP (2) JP7425041B2 (fr)
KR (1) KR20210043607A (fr)
CN (1) CN112702991A (fr)
AU (2) AU2019316575B2 (fr)
BR (1) BR112021002506A2 (fr)
CA (1) CA3108693A1 (fr)
EA (1) EA202190482A1 (fr)
IL (1) IL280642B2 (fr)
MA (1) MA53272A (fr)
MX (2) MX2021001554A (fr)
SG (1) SG11202100952QA (fr)
WO (1) WO2020033788A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1391707A (en) 1918-08-15 1921-09-27 Viviano Philip Automatic change-speed transmission
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2529623A1 (fr) 2003-06-16 2005-02-17 Celltech R & D, Inc. Anticorps specifiques de la sclerostine et methodes permettant d'accroitre la mineralisation osseuse
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
BRPI0620316A2 (pt) * 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
EP2114435A1 (fr) 2007-02-02 2009-11-11 Novartis AG Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
MY149129A (en) 2007-03-20 2013-07-15 Lilly Co Eli Anti-sclerostin antibodies
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2016109822A1 (fr) * 2014-12-31 2016-07-07 Novelmed Therapeutics, Inc. Formulation d'anticorps thérapeutiques aglycosylés
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation

Also Published As

Publication number Publication date
AU2025220748A1 (en) 2025-09-11
AU2019316575A1 (en) 2021-03-04
MX2026002664A (es) 2026-04-01
KR20210043607A (ko) 2021-04-21
IL280642B1 (en) 2025-05-01
JP2024045250A (ja) 2024-04-02
WO2020033788A1 (fr) 2020-02-13
EP3833327A1 (fr) 2021-06-16
IL280642A (en) 2021-03-25
CN112702991A (zh) 2021-04-23
BR112021002506A2 (pt) 2021-07-27
JP2021534117A (ja) 2021-12-09
US20240342288A1 (en) 2024-10-17
EA202190482A1 (ru) 2021-05-25
SG11202100952QA (en) 2021-02-25
JP7425041B2 (ja) 2024-01-30
AU2019316575B2 (en) 2025-05-22
IL280642B2 (en) 2025-09-01
CA3108693A1 (fr) 2020-02-13
US20210308265A1 (en) 2021-10-07
MX2021001554A (es) 2021-04-13

Similar Documents

Publication Publication Date Title
EP3795157A4 (fr) Composition pharmaceutique comprenant un inhibiteur d'egfr à petites molécules et son procédé de préparation
EP3909982A4 (fr) Anticorps cd73, son procédé de préparation et son application
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3862348A4 (fr) Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée
MA53920A (fr) Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
EP3778648A4 (fr) Nouvelle molécule d'anticorps, son procédé de préparation et son utilisation
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
EP3907001A4 (fr) Catalyseur pour une réaction d'hydrogénation et procédé de préparation associé
MA50239A (fr) Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
EP3485876A4 (fr) Composition pharmaceutique orale et procédé de production d'une formulation particulaire comprenant la composition
EP4045534A4 (fr) Anticorps, composition pharmaceutique et procédé
MA52704A (fr) Préparation pharmaceutique
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3808732A4 (fr) Procédé de préparation d'isocyanates aliphatiques
EP4015519A4 (fr) Procédé de préparation d'asénapine
EP3733648A4 (fr) Procédé de préparation d'acide 5r-benzyloxyaminopipéridin-2s-carboxylique ou d'un dérivé de celui-ci
EP4403573A4 (fr) Composition pharmaceutique comprenant un anticorps bispécifique anti-pvrig/tigit
EP3743072A4 (fr) Composition pharmaceutique pour administration à libération prolongée de buprénorphine
EP4062906A4 (fr) Composition pharmaceutique orale comprenant un composé carbamate et procédé de préparation de cette composition
MA53272A (fr) Procédé de préparation d'une formulation pharmaceutique d'anticorps
EP3612167A4 (fr) Procédé de préparation d'une forme posologique à désintégration orale
EP3988547A4 (fr) Dérivé d'indazole, son procédé de préparation et son application pharmaceutique
EP4026566A4 (fr) Composition pharmaceutique par voie orale comprenant du tériparatide et son procédé de préparation
EP4021920A4 (fr) Procédé amélioré pour la préparation de chlorhydrate d'ételcalcétide